These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 34233172)

  • 1. Sphingolipids in metabolic disease: The good, the bad, and the unknown.
    Green CD; Maceyka M; Cowart LA; Spiegel S
    Cell Metab; 2021 Jul; 33(7):1293-1306. PubMed ID: 34233172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingolipids: players in the pathology of metabolic disease.
    Cowart LA
    Trends Endocrinol Metab; 2009 Jan; 20(1):34-42. PubMed ID: 19008117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
    Holland WL; Summers SA
    Endocr Rev; 2008 Jun; 29(4):381-402. PubMed ID: 18451260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingosine-1-phosphate metabolism and intestinal tumorigenesis: lipid signaling strikes again.
    Oskouian B; Saba J
    Cell Cycle; 2007 Mar; 6(5):522-7. PubMed ID: 17361098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine 1-phosphate is a key metabolite linking sphingolipids to glycerophospholipids.
    Kihara A
    Biochim Biophys Acta; 2014 May; 1841(5):766-72. PubMed ID: 23994042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ORMDL in metabolic health and disease.
    Brown RDR; Spiegel S
    Pharmacol Ther; 2023 May; 245():108401. PubMed ID: 37003301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingolipids and Lipoproteins in Health and Metabolic Disorders.
    Iqbal J; Walsh MT; Hammad SM; Hussain MM
    Trends Endocrinol Metab; 2017 Jul; 28(7):506-518. PubMed ID: 28462811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Click reactions with functional sphingolipids.
    Fink J; Seibel J
    Biol Chem; 2018 Sep; 399(10):1157-1168. PubMed ID: 29908120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rewiring Endothelial Sphingolipid Metabolism to Favor S1P Over Ceramide Protects From Coronary Atherosclerosis.
    Manzo OL; Nour J; Sasset L; Marino A; Rubinelli L; Palikhe S; Smimmo M; Hu Y; Bucci MR; Borczuk A; Elemento O; Freed JK; Norata GD; Di Lorenzo A
    Circ Res; 2024 Apr; 134(8):990-1005. PubMed ID: 38456287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingolipids and glycerophospholipids - The "ying and yang" of lipotoxicity in metabolic diseases.
    Rodriguez-Cuenca S; Pellegrinelli V; Campbell M; Oresic M; Vidal-Puig A
    Prog Lipid Res; 2017 Apr; 66():14-29. PubMed ID: 28104532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.
    Ponnusamy S; Meyers-Needham M; Senkal CE; Saddoughi SA; Sentelle D; Selvam SP; Salas A; Ogretmen B
    Future Oncol; 2010 Oct; 6(10):1603-24. PubMed ID: 21062159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingolipids in neurodegeneration (with focus on ceramide and S1P).
    Wang G; Bieberich E
    Adv Biol Regul; 2018 Dec; 70():51-64. PubMed ID: 30287225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate.
    Kihara A; Mitsutake S; Mizutani Y; Igarashi Y
    Prog Lipid Res; 2007 Mar; 46(2):126-44. PubMed ID: 17449104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.
    Blaho VA
    Adv Exp Med Biol; 2020; 1274():101-135. PubMed ID: 32894509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate.
    Laviad EL; Albee L; Pankova-Kholmyansky I; Epstein S; Park H; Merrill AH; Futerman AH
    J Biol Chem; 2008 Feb; 283(9):5677-84. PubMed ID: 18165233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingolipids in cancer.
    Furuya H; Shimizu Y; Kawamori T
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):567-76. PubMed ID: 22005951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingolipids and their metabolism in physiology and disease.
    Hannun YA; Obeid LM
    Nat Rev Mol Cell Biol; 2018 Mar; 19(3):175-191. PubMed ID: 29165427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceramide and Sphingosine 1-Phosphate in Liver Diseases.
    Park WJ; Song JH; Kim GT; Park TS
    Mol Cells; 2020 May; 43(5):419-430. PubMed ID: 32392908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of bioactive sphingolipids in physiology and pathology.
    Gomez-Larrauri A; Presa N; Dominguez-Herrera A; Ouro A; Trueba M; Gomez-Muñoz A
    Essays Biochem; 2020 Sep; 64(3):579-589. PubMed ID: 32579188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceramides - Lipotoxic Inducers of Metabolic Disorders.
    Chaurasia B; Summers SA
    Trends Endocrinol Metab; 2015 Oct; 26(10):538-550. PubMed ID: 26412155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.